Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00733-x
Abstract: Ceritinib is a potent selective ALK inhibitor with a manageable safety profile. In anecdotal reports, ceritinib was associated with organizing pneumonia (OP), which could be confused with disease progression. We aimed to delineate the characteristics…
read more here.
Keywords:
organizing pneumonia;
ceritinib;
lung cancer;
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2017 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx045
Abstract: Introduction Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer is sensitive to tyrosine kinase inhibitors; however, resistance can develop. Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a subset…
read more here.
Keywords:
lymphoma kinase;
rearranged non;
kinase;
anaplastic lymphoma ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2023 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002403
Abstract: To the Editor: Anaplastic lymphoma kinase (ALK) fusion oncogene occurs in 3% to 7% of patients with non-small cell lung cancer (NSCLC), with the most common companion being echinoderm microtubule-associated protein-like 4. [1] Ceritinib is…
read more here.
Keywords:
lymphoma kinase;
ceritinib;
non small;
anaplastic lymphoma ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030255
Abstract: Rationale: Anaplastic lymphoma kinase (ALK) gene fusion, an important driver gene alteration leading to the development of lung cancer, occurs in 5% of nonsmall cell lung cancer (NSCLC) cases in China. In addition to echinoderm…
read more here.
Keywords:
fusion;
ceritinib;
lung;
slc8a1 downstream ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13168
Abstract: Genetic rearrangements of anaplastic lymphoma kinase contribute to the pathogenesis of non‐small‐cell lung cancer; the anaplastic lymphoma kinase inhibitor, ceritinib, is widely used, as it is effective even in patients with non‐small‐cell lung cancer resistant…
read more here.
Keywords:
japanese adverse;
drug event;
report database;
ceritinib ... See more keywords
Photo by cdc from unsplash
Sign Up to like & get
recommendations!
1
Published in 2019 at "Internal Medicine"
DOI: 10.2169/internalmedicine.2597-18
Abstract: A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed…
read more here.
Keywords:
treatment;
lung disease;
ceritinib;
interstitial lung ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2018 at "In Vivo"
DOI: 10.21873/invivo.11418
Abstract: Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such…
read more here.
Keywords:
alk positive;
ceritinib;
non small;
positive non ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Future oncology"
DOI: 10.2217/fon-2017-0441
Abstract: AIM Ceritinib was evaluated within a compassionate use program of Italian patients. PATIENTS & METHODS 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. RESULTS Overall response was 40.6%, median progression-free…
read more here.
Keywords:
lymphoma kinase;
compassionate use;
anaplastic lymphoma;
ceritinib ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.939959
Abstract: Background Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), who are at the risk of developing bone metastasis. During bone metastasis, tumor cells release factors…
read more here.
Keywords:
bone loss;
effect ceritinib;
osteoclast formation;
ceritinib ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2017 at "Indian journal of cancer"
DOI: 10.4103/ijc.ijc_186_17
Abstract: Ceritinib is a novel ALK inhibitor approved for advanced stage NSCLC with ALK gene rearrangement, progressed and/or intolerant to crizotinib. 13 patients were included in our study who received ceritinib. Majority of them were women…
read more here.
Keywords:
lymphoma kinase;
anaplastic lymphoma;
crizotinib;
ceritinib ... See more keywords